Wells Fargo’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $468 | Hold |
200
| – | – | ﹤0.01% | 6402 |
|
|
2025
Q4 | $466 | Hold |
200
| – | – | ﹤0.01% | 6341 |
|
|
2025
Q3 | $376 | Hold |
200
| – | – | ﹤0.01% | 6316 |
|
|
2025
Q2 | $580 | Hold |
200
| – | – | ﹤0.01% | 6361 |
|
|
2025
Q1 | $144 | Hold |
200
| – | – | ﹤0.01% | 6350 |
|
|
2024
Q4 | $206 | Hold |
200
| – | – | ﹤0.01% | 6359 |
|
|
2024
Q3 | $268 | Sell |
200
-800
| -80% | -$1.07K | ﹤0.01% | 6212 |
|
|
2024
Q2 | $1.3K | Buy |
1,000
+460
| +85% | +$694 | ﹤0.01% | 6071 |
|
|
2024
Q1 | $929 | Buy |
540
+7
| +1% | +$11 | ﹤0.01% | 6168 |
|
|
2023
Q4 | $784 | Buy |
533
+18
| +3% | +$21 | ﹤0.01% | 6286 |
|
|
2023
Q3 | $623 | Sell |
515
-14
| -3% | -$19 | ﹤0.01% | 6320 |
|
|
2023
Q2 | $767 | Buy |
529
+18
| +4% | +$31 | ﹤0.01% | 6388 |
|
|
2023
Q1 | $741 | Buy |
511
+103
| +25% | +$172 | ﹤0.01% | 6459 |
|
|
2022
Q4 | $706 | Buy |
408
+5
| +1% | +$9 | ﹤0.01% | 6288 |
|
|
2022
Q3 | $0 | Sell |
403
-488
| -55% | -$485 | ﹤0.01% | 7309 |
|
|
2022
Q2 | $1K | Sell |
891
-13,392
| -94% | -$38.9K | ﹤0.01% | 6595 |
|
|
2022
Q1 | $124K | Sell |
14,283
-8,411
| -37% | -$86.2K | ﹤0.01% | 5213 |
|
|
2021
Q4 | $363K | Buy |
22,694
+14,928
| +192% | +$237K | ﹤0.01% | 4919 |
|
|
2021
Q3 | $144K | Sell |
7,766
-32,081
| -81% | -$515K | ﹤0.01% | 5238 |
|
|
2021
Q2 | $556K | Buy |
39,847
+21,927
| +122% | +$306K | ﹤0.01% | 4561 |
|
|
2021
Q1 | $265K | Sell |
17,920
-23,879
| -57% | -$420K | ﹤0.01% | 5029 |
|
|
2020
Q4 | $811K | Buy |
41,799
+8,424
| +25% | +$131K | ﹤0.01% | 4181 |
|
|
2020
Q3 | $373K | Sell |
33,375
-3,811
| -10% | -$45.1K | ﹤0.01% | 4562 |
|
|
2020
Q2 | $503K | Buy |
37,186
+10,390
| +39% | +$117K | ﹤0.01% | 4317 |
|
|
2020
Q1 | $217K | Buy |
26,796
+7,171
| +37% | +$63.2K | ﹤0.01% | 4631 |
|
|
2019
Q4 | $189K | Buy |
19,625
+2,351
| +14% | +$25.4K | ﹤0.01% | 4987 |
|
|
2019
Q3 | $183K | Buy |
17,274
+3,614
| +26% | +$38.1K | ﹤0.01% | 5010 |
|
|
2019
Q2 | $157K | Buy |
13,660
+8,915
| +188% | +$107K | ﹤0.01% | 5106 |
|
|
2019
Q1 | $61K | Sell |
4,745
-9,495
| -67% | -$101K | ﹤0.01% | 5273 |
|
|
2018
Q4 | $88K | Buy |
14,240
+11,906
| +510% | +$96.4K | ﹤0.01% | 5342 |
|
|
2018
Q3 | $25K | Buy |
2,334
+1,517
| +186% | +$17.6K | ﹤0.01% | 5780 |
|
|
2018
Q2 | $12K | Sell |
817
-236
| -22% | -$3.02K | ﹤0.01% | 5919 |
|
|
2018
Q1 | $15K | Buy |
1,053
+63
| +6% | +$764 | ﹤0.01% | 5871 |
|
|
2017
Q4 | $11K | Buy |
+990
| New | +$12.2K | ﹤0.01% | 5910 |
|
Other funds holding SPRO
GP
P
VCM
AI
AFM
Wells Fargo's SPRO Position: Q1 2026 in Review
Wells Fargo held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 200 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #6402.
Wells Fargo first reported a position in SPRO in Q4 2017 and has held it in 34 quarters since. The position peaked at $811K in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.
- Wells Fargo held 200 shares of Spero Therapeutics worth $468 as of Q1 2026.
- Wells Fargo left its Spero Therapeutics share count unchanged in Q1 2026.
- Spero Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6402 holding.
- Wells Fargo first reported a position in Spero Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Wells Fargo's Spero Therapeutics position peaked at $811K in Q4 2020.
- 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.